Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Proactive Investors Lifesciences Webinar (September 2021)
15 slides from Amplia Therapeutics's conference presentation, Sep 28, 2021
Slide 1: Amplia Presentation for Proactive Investors Lifesciences Webinar (ASX release)
ABN 16 165 160 841 ASX RELEASE 28 September 2021 For personal use only Amplia Presentation for Proactive Investors Lifesciences Webinar Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to provide the presentation that will be will be delivered at the Proactive Investors
Slide 2: Amplia Therapeutics (ASX:ATX) September 2021
For personal use only Amplia Therapeutics (ASX:ATX) September 2021 Amplia Therapeutics Limited
Slide 3: Disclaimer
Disclaimer For personal use only The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. No representation or warranty, express or implied, is mad
Slide 4: Amplia Therapeutics is developing new treatments for cancer and fibrosis
For personal use only Amplia Therapeutics is developing new treatments for cancer and fibrosis 3
Slide 5: Six Reasons to Invest in Amplia
Six Reasons to Invest in Amplia For personal use only Market cap. with headroom for growth Forthcoming milestones Highly experienced team Diversified product pipeline Best in class clinical-stage asset Addressing seriously unmet medical needs
Slide 6: A pipeline built for growth
A pipeline built for growth For personal use only DRUG INDICATION THERAPY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 & APPROVAL AMP945 Pancreatic cancer Combination therapy AMP945 Idiopathic pulmonary Monotherapy fibrosis (IPF) AMP945 Other cancers & Combo/Mono fibrotic diseases therapies AMP886 Cancers &
Slide 7: Unmet needs: Amplia's current focus
Unmet needs: Amplia’s current focus For personal use only Pancreatic Cancer Idiopathic Pulmonary Fibrosis (IPF) • 60,000 new diagnoses from pancreatic cancer in • Affects ~3M people worldwide the US each year • Devastating, progressive disease caused by the • Difficult-to-treat cancer that is often
Slide 8: Why target pancreatic cancer and pulmonary fibrosis?
Why target pancreatic cancer and pulmonary fibrosis? For personal use only Pancreatic Cancer Pulmonary Fibrosis Preclinical data provides rationale for clinical study in this disease AMP945 enhances the efficacy in animal models AMP945 effective in mouse model of IPF Gateway indication to other fibr
Slide 9: Recent deals for anti-fibrotic and pancreatic cancer drugs
Recent deals for anti-fibrotic and pancreatic cancer drugs For personal use only Total disclosed upfront and milestones payments; excludes potential royalty US$1,300M payments US$870M US$785M US$20M + US$380M US$80M + milestones R&D US$235M Year 2021 2020 2020 2019 2019 2019 2019 Deal Licensing/R&D
Slide 10: Successful Phase 1 clinical trial
Successful Phase 1 clinical trial For personal use only • AMP945 was safe and well-tolerated at all doses tested • 56 participants: single and multiple doses • No Serious Adverse Events • Oral dosing • Once-a-day • No food effect • Supports advancing AMP945 into Phase 2 clinical trials • Planning fo
Slide 11: Planned clinical trial in pancreatic cancer
Planned clinical trial in pancreatic cancer For personal use only • The trial will test current chemotherapy* + AMP945 • Pancreatic cancer patients with Stage 3 or 4 disease • Inoperable or metastatic disease • Approx. 60 first-line cancer patients • Trial will assess • Preliminary efficacy of AMP94
Slide 12: Benefits of developing AMP945 as first-line therapy
Benefits of developing AMP945 as first-line therapy For personal use only Largest patient population: >70% newly diagnosed “With the exception of two targeted patients agents, which exhibited minimal or no • Largest addressable market opportunity overall survival benefit (erlotinib and • Aids recrui
Slide 13: Amplia's clinical trial schedule
Amplia’s clinical trial schedule For personal use only CY2021 CY2022 CY2023 CY2024 Activity Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Pancreatic Cancer Drug Product Development Drug Interaction Studies HREC Filing IND filing Patient Recruitment Interim Analysis Pulmonary Fibrosis Extended Toxicology
Slide 14: Amplia summary
Amplia summary For personal use only • Amplia Therapeutics is an exciting company with a diversified product pipeline and high quality prospects in clinical development • Multiple value inflexions expected in the next 2-3 years • AMP945 has completed a Phase 1 trial and is now poised for development
Slide 15: Thank you
For personal use only THANK YOU ampliatx.com
Amplia Therapeutics — Proactive Investors Lifesciences Webinar (September 2021) on 6ix